|
|
| 1. |
Right Ventricular Myxoma Obstructing the Right Ventricular Outflow Tract |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 14-15
Jeffrey Kern,
Flor Aguilera,
Diane Carlson,
Mark Galantowicz,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 2. |
Effects of Walking on Coronary Heart Disease in Elderly Men |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 16-16
Hannes Gaenzer,
Wolfgang Sturm,
Guenther Neumayr,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 3. |
Risk of Cocaine-Induced Myocardial Infarction During Sport |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 17-17
Arthur Siegel,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 4. |
Late Results of Percutaneous Balloon Mitral Valvuloplasty: The Chinese Experience |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 18-18
Bernard Iung,
Eric Garbarz,
Pierre Michaud,
Steeven Helou,
Bruno Farah,
Patricia Berdah,
Pierre-Louis Michel,
Bertrand Cormier,
Alec Vahanian,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 5. |
Is the Corrected TIMI Frame Count an Independent Predictor of Adverse Outcome? |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 19-19
C. Gibson,
Sabina Murphy,
Michael Rizzo,
Kathryn Ryan,
Susan Marble,
Carolyn McCabe,
Christopher Cannon,
Frans Van de Werf,
Eugene Braunwald,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 6. |
Coronary Calcium Does Not Accurately Predict Near-Term Future Coronary Events in High-Risk Adults |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 20-20
Robert Detrano,
Nathan Wong,
Terence Doherty,
Robert Shavelle,
Weiyi Tang,
Leonard Ginzton,
Matthew Budoff,
Kenneth Narahara,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 7. |
CirculationElectronic PagesJuly 11, 2000 |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 143-143
James Willerson,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 8. |
Postscripts From the Post Coronary Artery Bypass Graft Trial : The Sustained Benefit of More Aggressive Cholesterol Lowering and the Enigma of Low-Dose Anticoagulation |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 144-144
David Waters,
Rabih Azar,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 9. |
Acute and Delayed Benefits of &bgr;-Blockers During Coronary Intervention : True, True and Unrelated |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 147-147
George Vetrovec,
Preview
|
|
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
| 10. |
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial |
| |
Circulation: Journal of the American Heart Association,
Volume 102,
Issue 2,
2000,
Page 149-156
Christopher Cannon,
Carolyn McCabe,
Robert Wilcox,
Anatoly Langer,
Abraham Caspi,
Peter Berink,
Jose Lopez-Sendon,
Jiri Toman,
Andrew Charlesworth,
Robert Anders,
John Alexander,
Allan Skene,
Eugene Braunwald,
Preview
|
|
摘要:
BackgroundAlthough intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events.Methods and ResultsInvestigators at 888 hospitals in 29 countries enrolled 10 288 patients with acute coronary syndromes, which was defined as ischemic pain at rest within 72 hours of randomization, associated with positive cardiac markers, electrocardiographic changes, or prior cardiovascular disease. Patients received aspirin and were randomized to receive, for the duration of the trial, (1) 50 mg of orbofiban twice daily (50/50 group), (2) 50 mg of orbofiban twice daily for 30 days followed by 30 mg of orbofiban twice daily (50/30 group), or (3) a placebo. The primary composite end point was death, myocardial infarction, recurrent ischemia requiring rehospitalization, urgent revascularization, or stroke. The trial was terminated prematurely because of an unexpected increase in 30-day mortality in the 50/30 orbofiban group. Mortality through 10 months was 3.7% for the placebo group versus 5.1% in the 50/30 group (P=0.008) and 4.5% in the 50/50 group (P=0.11). There were no differences in the primary end point (22.9%, 23.1%, and 22.8%, for the placebo, 50/30, and 50/50 groups, respectively). Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2.0%, 3.7% (P=0.0004), and 4.5% (P<0.0001) of patients, respectively. Exploratory subgroup analyses found that patients who underwent percutaneous coronary intervention had a lower mortality and a significant reduction in the composite end point (P=0.001) with orbofiban.ConclusionsFixed-dose orbofiban failed to reduce major cardiovascular events and was associated with increased mortality in this broad population of patients with acute coronary syndromes; however, a benefit was observed among patients who underwent percutaneous coronary intervention.
ISSN:0009-7322
出版商:OVID
年代:2000
数据来源: OVID
|
|
首页
